Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
about
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerMeta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapyReduced Let-7a Is Associated with Chemoresistance in Primary Breast CancerTowards non-invasive characterization of breast cancer and cancer metabolism with diffuse optics.Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.Preoperative Radiotherapy Is Not Associated with Increased Post-mastectomy Short-term Morbidity: Analysis of 77,902 Patients.Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.An objective nodal staging system for breast cancer patients undergoing neoadjuvant systemic treatment.Novel rapid-immunohistochemistry using an alternating current electric field for intraoperative diagnosis of sentinel lymph nodes in breast cancer.Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment.Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentUtilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer.The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation.Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction.Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?Current neoadjuvant treatment options for HER2-positive breast cancer.In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer.Bootcamp during neoadjuvant chemotherapy for breast cancer: a randomized pilot trial.Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series.Impact of neoadjuvant chemotherapy on wound complications after breast surgeryComparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG.Breast Cancer: State of the Art and New Findings.Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model.The Value of Combined Large Format Histopathology Technique to Assess the Surgically Removed Breast Tissue following Neoadjuvant Chemotherapy: A Single Institution Study of 40 Cases.Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapyPatterns of Care for Localized Breast Cancer in Oklahoma, 2003-2006Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapyFactors that predict early treatment failure for patients with locally advanced (T4) breast cancer.Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literaturePredictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant TherapyNeoadjuvant Treatment in Patients with HER2-Positive Breast Cancer.Neoadjuvant chemotherapy and pathologic response: a retrospective cohortComparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
P2860
Q24597847-544A67DC-654C-4CBA-B013-63DFDB444FEFQ27024544-3366F903-B342-4B37-976C-7A0D96403F53Q28546834-F2C7F021-FD91-4430-9190-E50B71BDCCFEQ30435832-062264F6-C536-41B8-8BA2-7F539E75D577Q33388534-F98DD375-EB3A-4352-A507-A31028595477Q33601499-4B646C4B-8AAB-4F24-892D-EFA291DDAA8EQ33690733-B36B672A-708F-4774-BD1F-68C8BC75CE77Q33698446-07ECCBE7-925E-4BA1-882F-E02DAE0F6E19Q33750517-F28CFC58-D170-44C7-B0EC-5B2ADE689E39Q33765728-DDEE2C9B-A957-4CDA-9347-E3EDE99D9E73Q33996547-47A83367-D504-431C-8BB9-49EE52AEB67CQ34232366-6191D44E-DF55-4D6D-A664-04DD782B831BQ34256060-4FF9F2C1-4DE5-4303-8B8C-EF62D44CD223Q34331734-C1CE663A-8F4D-417A-8329-3122CD3A77D6Q35017523-9013F927-13F6-4115-B2A2-FFC1787D2980Q35078418-DBB7A626-9AD1-430E-B744-E5D5B3C212FDQ35093766-F04883EB-0386-4329-B61E-35F66D20D625Q35155591-0494C2DB-B365-40BA-9C21-39AD4DCBBEB3Q35160045-9AF8762A-2916-4FA0-9394-82B4906C58B0Q35164938-2A5F79DE-9352-446B-9AA3-E7CF9D67CBF1Q35345516-C49A51B4-6C2C-49F6-B952-DB3806D3A9F8Q35530220-BB2F5926-E1A1-40EC-B961-AF4C0635659AQ35560975-3D1B4A17-E3E9-4523-8C17-95FD79CCCAB3Q35789399-FCF9765F-BF9F-4ABB-B5F6-F0F83BEE94E4Q35789677-E2886DA1-F2CB-4F7C-A155-E6FEF661F6A6Q36024666-4FFAA2D2-BB93-4516-BAF5-C5119295F971Q36205095-5A56B4CA-790D-411F-A577-DEDDD2034B3EQ36214778-8E3A0CDE-A4A7-40DA-B7CB-C9030D2FE539Q36295112-1DF35A1C-D9E4-467C-BE91-136311048B3CQ36296828-B015C5CF-7DE2-4F97-BC47-611F68E68727Q36355682-13EBED74-9C7B-40E7-BE49-871C1074C536Q36515249-D7A04206-5016-4619-B51E-B2E58D799F52Q36560350-D1E77218-D834-417B-914E-F9F2B26A57CFQ36574920-6D13C66A-3634-4670-A8C1-8896484FFF68Q36696517-69C8E3C8-5241-489A-833F-59B448AE59F9Q36825817-EDED5870-4A42-48E8-AC56-7D5F9AB6BB73Q36853593-F1018684-4B25-4D8D-8D42-4955B6E45780Q36914142-9D825FBA-AA56-402B-8164-FE990FC264D0Q36935858-EC381209-C13F-48BE-94B3-59290C6B7CE3Q36976929-E44FED1C-1F2B-441E-A0DF-2BDF76C92C1C
P2860
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Recommendations from an intern ...... cancer: new perspectives 2006.
@en
type
label
Recommendations from an intern ...... cancer: new perspectives 2006.
@en
prefLabel
Recommendations from an intern ...... cancer: new perspectives 2006.
@en
P2093
P50
P356
P1433
P1476
Recommendations from an intern ...... cancer: new perspectives 2006.
@en
P2093
G von Minckwitz
H Bonnefoi
J-Y Pierga
M Colleoni
M Kaufmann
P304
P356
10.1093/ANNONC/MDM201
P577
2007-11-12T00:00:00Z